Related Experiment Video
Updated: Aug 14, 2026

Computational Prediction of Amino Acid Preferences of Potentially Multispecific Peptide-Binding Domains Involved in Protein-Protein Interactions
Published on: January 26, 2024
Residues distant from the active site influence protein-tyrosine phosphatase 1B inhibitor binding
Jacqueline Montalibet1, Kathryn Skorey, Dan McKay
1Department of Biochemistry and Molecular Biology, Merck Frosst Center for Therapeutic Research, Pointe-Claire, Quebec H9R 4P8, Canada.
Abstract:
Regions of protein-tyrosine phosphatase (PTP) 1B that are distant from the active site yet affect inhibitor binding were identified by a novel library screen. This screen was based on the observation that expression of v-Src in yeast leads to lethality, which can be rescued by the coexpression of PTP1B. However, this rescue is lost when yeast are grown in the presence of PTP1B inhibitors. To identify regions of PTP1B (amino acids 1-400, catalytic domain plus 80-amino acid C-terminal tail) that can affect the binding of the difluoromethyl phosphonate (DFMP) inhibitor 7-bromo-6-difluoromethylphosphonate 3-naphthalenenitrile, a library coexpressing PTP1B mutants and v-Src was generated, and the ability of yeast to grow in the presence of the inhibitor was evaluated. PTP1B inhibitor-resistant mutations were found to concentrate on helix alpha7 and its surrounding region, but not in the active site. No resistant amino acid substitutions were found to occur in the C-terminal tail, suggesting that this region has little effect on active-site inhibitor binding. An in-depth characterization of a resistant substitution localizing to region alpha7 (S295F) revealed that this change minimally affected enzyme catalytic activity, but significantly reduced the potency of a panel of structurally diverse DFMP PTP1B inhibitors. This loss of inhibitor potency was found to be due to the difluoro moiety of these inhibitors because only the difluoro inhibitors were shifted. For example, the inhibitor potency of a monofluorinated or non-fluorinated analog of one of these DFMP inhibitors was only minimally affected. Using this type of library screen, which can scan the nearly full-length PTP1B sequence (catalytic domain and C-terminal tail) for effects on inhibitor binding, we have been able to identify novel regions of PTP1B that specifically affect the binding of DFMP inhibitors.
Insights
Novel screening identified protein-tyrosine phosphatase 1B (PTP1B) regions distant from the active site that impact difluoromethyl phosphonate (DFMP) inhibitor binding. Mutations in helix alpha7, not the active site or C-terminal tail, confer resistance to these PTP1B inhibitors.
Area of Science:
- Biochemistry
- Enzyme kinetics
- Drug discovery
Background:
- Protein-tyrosine phosphatase 1B (PTP1B) is a key regulator of cellular signaling pathways.
- PTP1B is a validated target for therapeutic intervention in diseases such as diabetes and obesity.
- Understanding PTP1B inhibitor binding is crucial for developing more effective drugs.
Purpose of the Study:
- To identify regions of PTP1B, beyond the active site, that influence the binding of difluoromethyl phosphonate (DFMP) inhibitors.
- To characterize novel PTP1B mutations conferring resistance to DFMP inhibitors.
- To elucidate the structural basis for DFMP inhibitor binding to PTP1B.
Main Methods:
- A novel yeast-based genetic screen was employed using coexpression of PTP1B mutants and v-Src.
- Yeast growth in the presence of PTP1B inhibitors was used to identify inhibitor-resistant mutations.
- Resistant PTP1B mutants were characterized for alterations in catalytic activity and inhibitor potency.
Main Results:
- Mutations conferring resistance to DFMP inhibitors were identified in helix alpha7 and its surrounding regions, not within the active site or C-terminal tail.
- A specific mutation, S295F, minimally impacted PTP1B catalytic activity but significantly reduced the potency of DFMP inhibitors.
- The reduced potency was attributed to the difluoro moiety of the inhibitors, as monofluorinated or non-fluorinated analogs showed minimal changes.
Conclusions:
- Regions of PTP1B distant from the active site play a significant role in modulating DFMP inhibitor binding.
- Helix alpha7 is a critical region for the specific interaction with DFMP inhibitors.
- The findings provide insights into the allosteric regulation of PTP1B and inform the design of next-generation PTP1B inhibitors.
More Related Videos
09:40Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
Published on: September 28, 2018
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
Related Concept Videos
Factors Affecting Protein-Drug Binding: Drug Interactions
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Factors Affecting Protein-Drug Binding: Protein-Related Factors
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be bound by...
Ligand Binding and Linkage
Protein-Drug Binding: Mechanism and Kinetics
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Factors Affecting Protein-Drug Binding: Drug-Related Factors
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In contrast,...
Enzyme Inhibition